**Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis**

Miriam Saiz-Rodríguez 1,2,*†, Jorge Labrador 1,3,*†, Beatriz Cuevas 3, David Martínez-Cuadrón 4,†, Verónica Campuzano 3, Raquel Alcaraz 1, Isabel Cano 4, Miguel A. Sanz 4, Mourad El Gharbi 4, and Pau Montesinos 4

1 Research Unit, Fundación Burgos por la Investigación de la Salud (FBIS), Hospital Universitario de Burgos, 09006 Burgos, Spain; rakaraz@hubu.es
2 Department of Health Sciences, University of Burgos, 09001 Burgos, Spain
3 Hematology Department, Hospital Universitario de Burgos, 09006 Burgos, Spain; bceuvas@saludcastillayleon.es (B.C.); vcampuzano@saludcastillayleon.es (V.C.)
4 Hematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain; martinez_davcu@gva.es (D.M.-C.); cano_isafer@gva.es (I.C.); Miguel.Sanz@uv.es (M.A.S.); montesinos_pau@gva.es (P.M.)
* Correspondence: msaiz@hubu.es (M.S.-R.); jlabradorg@saludcastillayleon.es (J.L.)
† These authors have equally contributed to this paper and should be considered as first authors.

**Simple Summary:** Azacitidine and decitabine have been increasingly used for the treatment of acute myeloid leukaemia in older patients. The choice between azacitidine and decitabine depends mostly on the experience and preference of the attending physician, since they have not been compared directly in a randomised clinical trial. In this study, we identified the best treatment regimen for each drug and compare the efficacy of decitabine and azacitidine monotherapy in newly diagnosed acute myeloid leukaemia. We found no significant differences regarding 1-year mortality and overall survival for azacitidine and decitabine (roughly 9 months). Moreover, there were no significant differences in the efficacy of 5-day versus 10-day schedules of decitabine. However, patients treated with the shortened 5-day azacitidine scheme showed worsened outcomes compared to the standard 7-day regimen. Hopefully, our results might be helpful for the design of azacitidine/decitabine-based combination schedules to be tested in future trials.

**Abstract:** Irruption of decitabine and azacitidine has led to profound changes in the upfront management of older acute myeloid leukaemia (AML). However, they have not been directly compared in a randomised clinical trial. In addition, there are no studies comparing the optimal treatment schedule of each drug in AML. A systematic review and meta-analysis on the efficacy of decitabine and azacitidine monotherapy in newly diagnosed AML was conducted. Randomised controlled trials and retrospective studies were included. A total of 2743 patients from 23 cohorts were analysed (10 cohorts of azacitidine and 13 of decitabine). Similar response rates were observed for azacitidine (38%, 95% CI: 30–47%) compared to decitabine (40%, 95% CI: 32–48%) ($p = 0.0825$). Overall survival (OS) between azacitidine (10.04 months, 95% CI: 8.36–11.72) and decitabine (8.79 months, 95% CI: 7.62–9.96) was also similar ($p = 0.386$). Patients treated with azacitidine showed a lower median OS when azacitidine was administered for 5 days (6.28 months, 95% CI: 4.23–8.32) compared to the standard 7-day schedule (10.83 months, 95% CI: 9.07–12.59, $p = 0.002$). Among patients treated with decitabine, response rates and OS were not significantly different between 5-day and 10-day decitabine regimens. Despite heterogeneity between studies, we found no differences in response rates and OS in AML patients treated with azacitidine or decitabine.

**Keywords:** azacitidine; decitabine; meta-analysis; acute myeloid leukaemia; elderly
1. Introduction

Acute myeloid leukaemia (AML) is a heterogeneous haematological malignant disease characterised by clonal abnormal proliferation of immature haematopoietic progenitor cells of the myeloid lineage [1]. AML is commonly acknowledged as a disease of older adults, the median age being 68 years old [2,3]. In fact, the incidence of AML in Europe is 3.7 per 100,000 among the general population but increases to 13.7 per 100,000 among people aged 65 or older [4].

Although advances in AML treatment have improved the overall outcome of patients, the prognosis for older patients remains poor [5,6], with roughly 70% of patients over the age of 65 dying within the first year of diagnosis [7]. The toxicity and the high treatment-related mortality associated with intensive chemotherapy, comorbidities and poorer performance status limit its use in the elderly [8]. In addition, older AML patients are more likely to have secondary AML, adverse cytogenetics or the multidrug resistance phenotype, which raises the issue of whether they should receive palliative care [9–12]. Acceptable options for older patients include low-dose Ara-C and hypomethylating agents (HMAs), which increase the proportion of patients receiving active therapy [6]. Epigenetic changes in AML, especially in aberrant DNA methylation, play a role in the regulation and expression of tumour suppressor genes and oncogenes [13]. As epigenetic changes, these aberrant modifications are reversible, making them potential therapeutic targets. Azacitidine and decitabine are pyrimidine nucleoside analogues that inhibit DNA methyltransferase, impairing DNA methylation. The clinical and biological efficacy of HMAs has been proven in numerous in vitro/in vivo studies and clinical trials [13,14]. Therefore, HMAs have been increasingly used for older AML patients. Their different mechanism of action associated with a manageable toxicity profile, low incidence of mortality and administration in the outpatient setting make them ideal agents for use in older patients [15].

Both azacitidine and decitabine are well tolerated, and they have shown improved overall survival compared with the best supportive care or low-dose Ara-C [16,17]. Despite the widespread use of these agents, there is no consensus regarding their comparative efficacy and clinical benefit, with notable between-study variability [1].

At present, the effectiveness of decitabine and azacitidine has not been compared directly in a randomised clinical trial. Indeed, the choice of HMA depends mostly on the experience and preference of the attending physician.

In addition, there are limited studies comparing the optimal treatment schedule of each drug in AML. Higher response rates have been reported with a 10-day schedule of decitabine [18], although these results have not been validated [19], leading to the need for randomised clinical trials comparing it with standard 5-day schedule. Similarly, studies have reported the efficacy of azacitidine with doses different from the standard 7-day schedule [20,21], but there are no randomised trials.

The scarcity of well-controlled studies performed in older AML patients accentuates the usefulness of well-conducted meta-analyses. In this systematic review and meta-analysis, the aim was to analyse and compare the efficacy of either decitabine or azacitidine monotherapy in newly diagnosed AML patients in order to shed light on the management of an already difficult-to-treat population. Moreover, this study also aimed to compare the efficacy and survival of a standard dose of azacitidine and decitabine versus other dose regimens for each drug.

2. Materials and Methods

The protocol for this study was developed a priori and registered in PROSPERO (ID CRD42020181405). This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements [22].

2.1. Eligibility Criteria

The study included randomised controlled trials and retrospective studies that recruited adults with newly diagnosed AML who were treated with either azacitidine or
decitabine monotherapy. Trials were selected if performed on patients not eligible for intensive chemotherapy. The meta-analysis only included data from the azacitidine or decitabine monotherapy arms; data from experimental arms were excluded from the analysis.

Studies were included if at least one of the following outcomes was reported: mortality, overall survival (OS), complete remission (CR), complete remission with incomplete haematological recovery (CRi) and partial response (PR).

2.2. Data Sources and Search Strategies

The literature search included the following databases: MEDLINE, EU Clinical Trials Register and ClinicalTrials.gov. We additionally reviewed the reference lists of the most relevant clinical studies and review articles in order to be as comprehensive as possible. The complete search strategy is provided in Supplementary Table S1.

2.3. Study Selection

Two independent reviewers (M.S.-R. and J.L.) independently screened all the titles and abstracts and evaluated each article based on the eligibility criteria. Disagreements were resolved by consensus and in concordance with a third reviewer (P.M.), when necessary. Studies that fulfilled the following criteria were included: (1) newly diagnosed AML patients’ cohorts in which azacitidine or decitabine was prescribed upfront and (2) studies reporting efficacy and outcome variables.

2.4. Data Extraction and List of Variables Included

Two reviewers (M.S.-R. and J.L.) independently extracted data using standardised forms created in Microsoft Excel 2010. These forms contained the following information:

- Study (first author, year)
- Study design: phase I, II or III clinical trial, retrospective, prospective
- Intervention (dose, schedule): azacitidine or decitabine
- Comparison (description): best supportive care, low doses of cytarabine
- Patients (N)
- Age (years): median and range
- Male (%)
- ECOG 0/1, 2, ≥3 (%): Eastern Cooperative Oncology Group (ECOG) scale
- AML type (%): de novo or secondary
- Cytogenetics (%): favourable, intermediate, adverse
- BM blasts (median %): bone marrow blasts
- WBC count (10⁹/L median): white blood cell count
- CR (%): complete remission
- CCR (%): composite complete remission rate (CR + CRi)
- PR (%): partial response
- ORR (%): overall response rate (CR + CRi + PR)
- Median OS (months): overall survival
- Early mortality (first 30 and 60 days since randomisation) (%)
- Mortality (%) (2.5. Definitions

The definition of CR was consistently applied to all studies as the bone marrow blast count <5%, absence of circulating blasts and blasts with Auer rods; the absence of extramedullary disease; absolute neutrophil count >1.0 × 10⁹/L; and platelet count >100 × 10⁹/L [23]. CR/CRi included patients with a CR and patients who met all CR criteria but only one of these: absolute neutrophil count >1.0 × 10⁹/L or platelet count >100 × 10⁹/L, which is considered CRi. The OS was included when counting all deaths regardless of the cause and whether the patient received subsequent therapy. When the OS was not explicitly reported in the studies, it was estimated from Kaplan–Meier curves, if
available. Early mortality data registered comprised 30-day mortality and 60-day mortality (proportion of patients who died within the first 30/60 days of treatment).

2.6. Methodologic Quality and Risk of Bias

We used Cochrane Collaboration’s tool for bias assessment [24], which includes the following items: random sequence generation, allocation concealment, selective reporting, blinding (of participants and personnel and of outcome assessment), incomplete outcome data and other sources of bias. This tool allows the classification of the risk of bias as low, unclear or high. Two reviewers (M.S.-R. and J.L.) independently assessed the risk of bias for each study. Disagreements were solved by consensus or by the intervention of a third reviewer (P.M.).

2.7. Statistical Analysis

Analyses were performed using Epidat v.3.1 software or STATA v.15 software, where applicable. For the estimation of variability, the following measurements were used: inter-study variance, intra-study variance and inter-study coefficient of variation. The $I^2$ coefficient, representing the proportion of total variance explained by the inter-study variance, was used as the main estimator of variability, with $I^2 > 50\%$ suggesting substantial heterogeneity. For evaluation of the ORR, mortality and OS, a random effects meta-analysis was performed according to the studies’ variability in outcomes for all endpoints. The results were summarised using a point estimate and the 95% confidence interval (CI). For analysis of the OS, the median and CI were transformed into the mean and SD, as described by Hozo et al. [25]. All analyses were based on the intention-to-treat (ITT) principle.

3. Results

3.1. Study Selection

The search strategy retrieved 819 citations before removal of duplicates. The PRISMA flowchart of the selection procedure and the main reasons for exclusion are detailed in Figure 1.

![Figure 1. Flowchart of study selection procedure and the main reasons for article exclusion.](image_url)

| Main reason for exclusion | Azacitidine | Decitabine | Total |
|---------------------------|-------------|------------|-------|
| Study design              | 5           | 5          | 10    |
| Missing data              | -           | 2          | 2     |
| Duplicate studies         | 2           | 2          | 4     |
| Type of participants      | 5           | 2          | 7     |
| Type of intervention      | 4           | 4          | 8     |
| Total excluded            | 14          | 15         | 29    |

3.2. Study Characteristics

A total of 2743 patients, from 23 cohorts (10 of azacitidine and 13 of decitabine), from 22 studies, were analysed. The characteristics of the included studies are depicted in Table 1, and the efficacy outcomes are shown in Table 2.
Table 1. Patient characteristics of studies included in the meta-analysis.

| Variable | Study (First Author, Year) | Study Design | Intervention | Comparison | Patients (N) | Age (Years) | Male (%) | ECOG 0/1, 2, ≥3 | AML Type, DN, S (%) | Cytogenetics F, I, A (%) | NPM1 (M, W, NA) (%) | FLT3 (M, W, NA) (%) | BM Blasts (%) | WBC Count (10⁹/L) |
|----------|---------------------------|--------------|--------------|------------|--------------|-------------|----------|----------------|-----------------|------------------|-----------------|-----------------|-----------------|-------------|----------------|
| Azacitidine | Al-Ali, 2012 [20] | Phase I/II | 75 mg/m²/day SC for 5 days every 4 weeks | NA | 20 | 78 (64–84) | 55 | 40, 60 | 75, 25 | 15, 75, 10 | 15, 75, 10 | 44 (10–90) | 3.4 (0.8–187.3) |
| | DiNardo, 2020 [26] | Phase III | 75 mg/m²/day SC for 7 days every 4 weeks | Aza + Ven | 145 | 76 (60–90) | 60 | 56.44 | 76, 24 | 0, 61, 39 | 12, 47, 41 | 15, 59, 26 | |
| | Dombret, 2015 [17] | Phase III | 75 mg/m²/day SC for 7 days every 4 weeks | Conventional care regimen | 241 | 75 (64–91) | 57.7 | 77.2; 22.8 | 80, 20 | 0, 65, 35 | | | |
| | Falantes, 2017 [27] | Retrospective | 75 mg/m²/day SC for 7 days every 4 weeks | NA | 710 | 75 (60–93) | 63.1 | 65; 27.7 | 44, 56 | 1.5; 53.1; 31.3 | | | |
| | Fenaux, 2009 [28] | Phase III | 75 mg/m²/day SC for 7 days every 4 weeks | Conventional care regimen | 55 | 70 (52–80) | 67.3 | 92.7; 7.3 | | 34.5; 69.1; 25.5 | 23 (20–34) | |
| | Medeiros, 2017 [29] | Phase II | 75 mg/m²/day SC for 7 days every 4 weeks | Lenalidomide | 34 | 75 (66–85) | 55.9 | 79.4; 17.6 | 85.3; 14.7 | 50 | | 34 (14–70) |
| | Passweg, 2013 [21] | Phase III | 100 mg/m²/day SC for 5 days every 4 weeks | NA | 45 | 74 (55–86) | 60 | | | | | | 2.9 (1.2–43.3) |
| | Sadashiv, 2014 [30] | Phase II | 100 mg/m²/day SC for 5 days every 4 weeks | NA | 15 | 74 (64–82) | 60 | 60; 33, 3 | | 44 (29–92) | | |
| | van der Herlhm, 2011 [31] | Retrospective | 75 mg/m²/day SC for 7 days every 4 weeks | NA | 31 | 71 (40–84) | 74 | 0; 68, 32 | | | | |
| | Vives, 2021 [32] | Phase III | 75 mg/m²/day subcutaneously for 7 days every 4 weeks | FLUGA | 142 | 74 (65–90) | 60 | 75.25 | 79; 21 | | | 52 (10–99) | 4.5 (0.6–235.5) |
Table 1. Cont.

| Variable | Study Design (First Author, Year) | Study | Intervention | Comparison | Patients (N) | Age (Years) | Male (%) | ECOG 0/1, 2, ≥3 | AML Type, DN, S (%) | Cytogenetics E, I, A (%) | NPM1 (M, W, NA) (%) | FLT3 (M, W, NA) (%) | BM Blasts (%) | WBC Count (10^9/L) |
|----------|----------------------------------|-------|--------------|------------|--------------|-------------|-----------|-----------------|------------------------|------------------------|------------------------|------------------------|------------------|------------------|
|          |                                  |       |              |            | NA           | 45          | 74 (52–87) | 56              | 58; 42                 | 2; 42; 53              | 4; 49; 47              | 13; 62; 24              | 49 (18–96)     | 7.7 (0.8–117.2) |
|          |                                  |       |              |            | NA           | 53          | 74 (60–85) | 64              |                        |                        |                        |                        | 52 (20–92)     | 2.7 (0.4–150.0) |
|          |                                  |       |              |            | NA           | 306         | 75 (65–90) | 59.5; 40.5     |                        |                        |                        |                        | 4.5 (1.8–17.1) |                 |
| Decitabine |                                  |       |              |            | NA           | 72          | 74 (44–88) | 68              |                        |                        |                        |                        | 3.0             |                 |
|          |                                  |       |              |            | NA           | 55          | 74 (61–87) | 50              | 82; 18                 | 55; 42                 | 53; 45                 | 50 (0–99)              | 2.7 (1–111)    |                 |
|          |                                  |       |              |            | NA           | 75          | 74          | 53.3            | 88; 12                 | 56; 44                 |                        |                        | 11.4; 88.6      | 3.4 (0.8–25.5) |
|          |                                  |       |              |            | DEC + valproic acid | 62         | 70 (38–83) |               |                        |                        |                        |                        |                 |                 |
|          |                                  |       |              |            | LDC          | 15          | 65 (60–80) | 80              | 53.3; 46.7             | 87; 13                 |                        |                        | 40              |                 |
|          |                                  |       |              |            | TC           | 242         | 73.0 (64.0–89.0) | 56.6 | 76; 24 | 64; 36 | 63.1; 36.1 | 3.10 (0.3–127.0) |
|          |                                  |       |              |            | NA           | 227         | 72 (56–86) | 61.2            | 77; 22.1; 0.9           | 7.3; 92.6              | 7.9; 89                | 56 (10–100)         | 4.4 (0.5–241) |
|          |                                  |       |              |            | NA           | 227         | 72 (56–86) | 61.2            | 77; 22.1; 0.9           | 7.3; 92.6              | 7.9; 89                | 56 (10–100)         | 4.4 (0.5–241) |
| Variable   | Study (First Author, Year) | Study Design | Intervention                            | Comparison | Patients (N) | Age (Years) | Male (%) | ECOG 0/1, 2, ≥ 3 (%) | AML Type, DN, S (%) | Cytogenetics F, I, A (%) | NPM1 (M, W, NA) (%) | FLT3 (M, W, NA) (%) | BM Blasts (%) | WBC Count (10⁹/L) |
|------------|---------------------------|--------------|-----------------------------------------|------------|--------------|-------------|----------|---------------------|---------------------|----------------------|---------------------|---------------------|---------------------|---------------------|
| Decitabine | Roboz, 2018 [41]          | Phase II     | 20 mg/m²/day IV for 10 days every 4 weeks | Decitabine + bortezomib | 82 | 72.4 (60.7–92.3) | 62.2 | 76.8; 19.5; 3.7 | 69.5; 30.5 | 28.2; 26.8; 45.1 | 13.3 (0.4–212.7) |
|            | Short, 2018 (cohort 1) [19]| Phase II     | 20 mg/m²/day IV for 3 days every 4 weeks | NA         | 28 | 77 (70–80) | 64; 36 | 54; 46 | 4; 96 | 8; 92 | 40 (29–68) | 2.0 (1.5–3.9) |
|            | Short, 2018 (cohort 2) [19]| Phase II     | 20 mg/m²/day IV for 10 days every 4 weeks | NA         | 43 | 78 (69–82) | 70; 30 | 58; 42 | 19; 81 | 5; 95 | 46 (25–64) | 3.2 (1.9–10.6) |

Abbreviations: NA, not applicable; ECOG, Eastern Cooperative Oncology Group; AML, acute myeloid leukaemia; DN, de novo; S, secondary; F, favourable; I, intermediate; A, adverse; M, mutated; W, wild type; BM, bone marrow; WBC, white blood cell.
Table 2. Efficacy outcomes of the studies included in the meta-analysis.

| Variable | Study (First Author, Year) | CR (%) | CCR (%) | PR (%) | ORR (%) | Median OS (Months) | 30-Day Mortality (%) | 60-Day Mortality (%) | Mortality (%) |
|----------|---------------------------|--------|---------|--------|---------|-------------------|----------------------|---------------------|-------------|
| Azacitidine | Al-Ali, 2012 [20]            | 10     | 15      | 50     | 7.7 (0.2–14.8) | 61                  |                      |                     |              |
|          | DiNardo, 2020 [26]           | 17.9   | 28.3    |        | 9.6 (7.4–12.7) | 6                   |                      |                     |              |
|          | Dombret, 2015 [17]           | 19.5   | 27.8    | 1.2    | 48.5    | 12.1 (9.2–14.2)   | 6.6                  | 16.2               | 49.3         |
|          | Falantes, 2017 [27]          |        | 35.5    |        |         | 9.0 (8.8–11)      |                      |                     | 60.8         |
|          | Fenaux, 2009 [28]            | 18     |         |        | 24.5 (14.6–38) | 5.9                  | 8.8                  |                     | 48           |
|          | Medeiros, 2017 [29]          | 17.6   | 41.2    |        | 17.8    | 6 (3.4–7.8)       |                      |                     |              |
|          | Passweg, 2013 [31]           | 17.8   | 0       | 17.8   |         | 11.8 (0.4–30.3)   | 15                   |                     |              |
|          | Sadashiv, 2014 [30]          | 20     | 13      | 47     |         | 13.0 (9.9–16.2)   |                      |                     |              |
|          | van der Herlm, 2011 [31]     | 16     | 23      | 3      | 5.6     | 9.8 (5.6–14)      | 53                   |                     |              |
|          | Vives, 2021 [32]             | 9      | 13      | 28     | 50      | 9.0 (3.9–14.2)    | 4                    |                     |              |
|          | Bhatnagar, 2014 [33]         | 31     | 42      |        | 10.0 (7.9–11.9) |                     |                      |                     |              |
|          | Blum, 2010 [18]              | 47     | 64      |        | 13.7 (9–18)    |                      |                     |                     |              |
|          | Bocchia, 2019 [34]           | 23.2   | 14.7    | 10.5   | 5.6     | 19.4              |                      |                     |              |
|          | Bouligny, 2021 [35]          | 16.7   | 36.1    | 36.1   | 5.6     | 77.8              |                      |                     |              |
|          | Cashen, 2009 [36]            | 24     | 26      |        | 12.7 (0.1–22.5) |                      |                      |                     |              |
|          | Fili, 2019 [37]              | 31     | 11      | 42     | 9.6 (1–59.0)   |                      |                      |                     |              |
|          | Issa, 2004 [38]              |        |         |        | 5.5 (0.5–13)   |                      |                      |                     |              |
|          | Jacob, 2015 [39]             |        |         |        | 7.7 (6.2–9.2)  |                      |                      |                     |              |
|          | Kantarjian, 2012 [16]        | 15.7   | 25.6    | 2.5    | 5.3     | 5.6 (1–36.0)      |                      |                     |              |
|          | Lubbert, 2011 [40]           | 13.21  | 12.77   | 25.98  | 9       | 72                |                      |                     |              |
|          | Roboz, 2018 [41]             | 39     |         |        | 9.3 (5.8–12.2) |                      |                      |                     |              |
|          | Short, 2018 (cohort 1) [19]  | 29     | 4       | 0      | 43      | 5.5 (2.1–11.7)    | 4                    |                     | 21           |
|          | Short, 2018 (cohort 2) [19]  | 30     | 5       | 10.5   | 40      | 6.0 (1.9–11.7)    | 9                    |                     | 25           |

Abbreviations: CR, complete remission; CCR, composite complete remission rate; PR, partial response; ORR, overall response rate; OS, overall survival.
3.3. Outcomes

A significantly higher CR rate was observed for decitabine (25%, 95% CI: 20–30%) compared to azacitidine (16%, 95% CI: 12–19%) \((p = 0.005)\). However, these differences disappeared when analysing the CCR, which was 27% (95% CI: 17–38%) for decitabine and 23% (95% CI: 14–32%) for azacitidine \((p = 0.542)\). A lower ORR was observed for azacitidine (38%, 95% CI: 30–47%) compared to decitabine (40%, 95% CI: 32–48%) \((p = 0.825)\), both with high \(I^2\) coefficients (>82%) (Figure 2).

![Figure 2. Pooled analysis of the overall response rate (ORR).](image)

The mortality rate at 30 days was not statistically different between azacitidine (6%, 95% CI: 4–9%) and decitabine (7%, 95% CI: 5–9%) \((p = 0.724)\). However, a trend towards a lower mortality rate at 60 days was noticed for azacitidine (15%, 95% CI 11–19%) compared to decitabine (20%, 95% CI 16–23) \((p = 0.107)\).

Regarding 1-year mortality (Figure 3), we found no significant difference between azacitidine (57%, 95% CI: 50–65%) and decitabine (62%, 95% CI: 47–77%) \((p = 0.547)\). However, again high heterogeneity was observed between studies, being over 75% for both agents.

Figure 4 depicts the median OS of all studies, being 10.04 months for azacitidine (95% CI: 8.36–11.72 months) and 8.79 months for decitabine (95% CI: 7.62–9.96 months), with no statistical significance between them \((p = 0.386)\).
Figure 3. Pooled analysis of 1-year mortality.

Figure 4. Pooled analysis of overall survival (OS).

Comparative analyses were performed, including studies with the approved regimens of both drugs. Table 3 summarises the response outcomes, OS and 1-year mortality rate for azacitidine and decitabine approved regimens (75 mg/m² for 7 days, and 20mg/m² for 5 days, respectively, available in Supplementary Figures S1–S3). A significantly lower CR was observed for azacitidine (16%, 95% CI: 12%–20%) compared to decitabine (24%, 95% CI: 19%–29%).
18%–30%) \((p < 0.025)\). However, these differences did not remain significant for the ORR. The 1-year mortality was significantly different between azacitidine (54% mortality, 95% CI: 47%–61%) and decitabine (72% mortality, 95% CI: 67%–76%) \((p < 0.001)\). The median OS was 10.83 months (95% CI: 9.07–12.59 months) for azacitidine and 8.46 months (95% CI: 7.00–9.93 months) for decitabine \((p = 0.138)\).

**Table 3.** Summary of response outcomes, overall survival and mortality during azacitidine (75 mg/m², 7d) and decitabine treatment (20 mg/m², 5d) in monotherapy.

| Drug       | CR %, 95% CI | ORR %, 95% CI | 1-Year Mortality %, 95% CI | OS (Months) 95% CI |
|------------|--------------|---------------|----------------------------|-------------------|
| Azacitidine (75 mg/m², 7d) | 16% (12–20) | 41% (32–50) | 54% (47–61) | 10.83 (9.07–12.59) |
| Decitabine (20 mg/m², 5d) | 24% (18–30) | 46% (42–50) | 72% (67–76) | 8.46 (7.00–9.93) |
| p-value    | 0.025        | 0.327         | <0.001                    | 0.138             |

Abbreviation: CR, complete remission; ORR, overall response rate; OS, overall survival. \(I^2\) coefficient >50% suggests substantial heterogeneity.

No significant differences were found comparing the 5-day and 7-day regimens of azacitidine regarding the ORR (36%, 95% CI: 13–60% versus 41%, 95% CI: 32–50%, \(p = 0.727\)). However, the 1-year mortality rate was higher in patients following the 5-day regimen (72%, 95% CI: 61–82%) compared to the 7-day regimen (54%, 95% CI: 47–61%) \((p = 0.008)\). Additionally, the median OS was lower when the drug was administered for 5 days (6.28 months, 95% CI: 4.23 months–8.32 months) versus 7 days (10.83 months, 95% CI: 9.07 months–12.59 months) \((p = 0.002)\).

Again, no significant differences were found when the 5-day (approved) and 10-day regimens of decitabine were compared regarding the ORR (46%, 95% CI: 42–50% vs. 37%, 95% CI 29–46%, \(p = 0.088\)). We found no significant differences in mortality and the OS either.

A summary of the results is briefly depicted in Figure 5.

**Figure 5.** Summary of results. Abbreviation: ORR, overall response rate; OS, overall survival; STD, standard; Non-std, non-standard.
3.4. Risk of Bias

Overall, the risk of bias ranged from unclear to high. The risk of bias is shown in Figure 6.

| First author, year | Random sequence generation (selection bias) | Allocation concealment (selection bias) | Blinding (outcome assessment) (performance bias) | Blinding (outcome assessment) (detection bias) | Incomplete outcome data (attrition bias) | Selective reporting (reporting bias) |
|--------------------|------------------------------------------|--------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Al-Ali, 2012       | High                                     | High                                 | Low                             | Low                             | Low                             | Low                             |
| Diniardo, 2020     | Low                                      | Low                                  | Low                             | Underar                        | Low                             | Low                             |
| Donibret, 2015     | Low                                      | Underar                              | Underar                         | Underar                        | Low                             | Low                             |
| Fenaux, 2017       | High                                     | High                                 | Low                             | Low                             | Low                             | Low                             |
| Meier, 2017        | Low                                      | Low                                  | Underar                         | Underar                        | Low                             | Low                             |
| Passweg, 2013      | High                                     | High                                 | Low                             | Low                             | Low                             | Low                             |
| Saadzho, 2014      | Underar                                  | Low                                  | Low                             | Low                             | Low                             | Low                             |
| Vallecchi, 2011    | High                                     | Low                                  | Low                             | Underar                        | Low                             | Low                             |
| Vos, 2021          | Low                                      | Low                                  | High                            | Underar                        | Underar                        | Underar                        |
| Vos, 2020          | Underar                                  | Underar                              | Underar                         | Underar                        | Low                             | Low                             |
| Bacchi, 2015       | High                                     | Low                                  | High                            | Underar                        | Low                             | Low                             |
| Bessey, 2021       | High                                     | High                                 | Underar                         | Underar                        | Low                             | Low                             |
| Cashen, 2009       | High                                     | High                                 | Low                             | Low                             | Low                             | Low                             |
| Fil, 2019          | High                                     | High                                 | High                            | Underar                        | Underar                        | Underar                        |
| Ias, 2014          | High                                     | Low                                  | High                            | High                            | Low                             | Low                             |
| Jacob, 2015        | High                                     | High                                 | Low                             | High                            | Underar                        | Underar                        |
| Kantarjian, 2012   | Low                                      | Low                                  | High                            | Low                             | Low                             | Low                             |
| Lubbert, 2013      | High                                     | High                                 | High                            | Low                             | Low                             | Low                             |
| Robin, 2018        | High                                     | High                                 | High                            | Low                             | Low                             | Low                             |
| Short, 2018 (cohort 1) | Low                                    | Low                                  | High                            | High                            | Low                             | Low                             |
| Short, 2018 (cohort 2) | Low                                    | Low                                  | High                            | High                            | Low                             | Low                             |

Figure 6. Risk of bias.

4. Discussion

In this systematic review and meta-analysis, we analysed the effectiveness of 23 cohorts including 2743 AML patients treated with upfront azacitidine or decitabine monotherapy in the context of randomised controlled trials and retrospective studies.

As far as we know, this is the first meta-analysis comparing all published pooled azacitidine and decitabine studies according to dose regimens for each drug. Although we found no significant differences in survival between azacitidine and decitabine therapy, the results of this meta-analysis support the effectiveness of the standard dose schemes of these drugs over other dosages.

The efficacy of both HMAs has been compared in two recent studies: (1) a population-based study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database [42] and (2) a network meta-analysis including 538 patients treated with HMAs from three randomised controlled trials (two for azacitidine and one for decitabine) [43]. Our review includes all randomised clinical trials and retrospective studies (10 for azacitidine and 13 for decitabine, including 2743 patients), and evaluates different dose schedules, which provides a more complete picture of the efficacy of HMAs.

The scarcity of well-controlled studies performed in the older AML population underscores the need for well-conducted meta-analyses. Given that most of the available studies report on small patient samples, it seems mandatory to group all available cohorts. The main limitation of this study was the inclusion of retrospective single-centre studies, increasing the risk of selection bias and heterogeneity. Moreover, data were included from all reported azacitidine and decitabine treatment regimens, but the comparison between the approved regimens and others could have addressed this issue. Accordingly, the results of this meta-analysis may be useful to estimate the effectiveness of HMA monotherapy.
but may not necessarily apply to new combinations. However, since HMAs are being used as the backbone for novel combinations, the HMA dose schedule that could be more appropriate to combine (e.g., the less toxic and/or more efficacious HMA according to the partner agent) could be selected.

The current analysis confirmed moderate disease control with HMA monotherapy (pooled CR rate 21% (95% CI: 17–25%)). A prior phase 3 trial of decitabine showed a CR rate of 15.7% and a CCR of 25.6%, whereas in another phase 3 trial, azacitidine achieved a CR of 19.5% and a CCR of 27.8% [16,17]. The ORR of these phase 3 trials for azacitidine and decitabine was 31.1% and 45.9%, respectively, which was similar to that observed in this study (38% for azacitidine and 40% for decitabine). Of note, when standard dose schedules of both agents were compared, the ORR found in this meta-analysis, which included retrospective and real-life studies, was identical to that of the phase 3 trials (41% for azacitidine and 46% for decitabine). This difference was not statistically significant.

The presence of p53 mutation leads to extremely poor prognosis [44,45]. Bories et al. described a worse OS in patients with any p53 mutation and treated with azacitidine but found no association for response [46]. Regarding the use of decitabine in p53-mutated AML, Welch et al. found a higher response rate in patients with p53 mutations compared to wild-type patients after 10-day treatment (100% and 41%, respectively) [47]. Aldoss et al. described a comparable response rate between patients treated with venetoclax in combination with either a 5- or a 10-day regimen of decitabine [48]. As these results are not profoundly conclusive, the systematic classification of patients with p53 mutations will merit further investigation in conventional therapy and in the emerging field of p53-pathway-targeted therapies [46].

Although higher response rates have been initially reported with a 10-day schedule of decitabine [18], a recent phase II study did not confirm this superiority in comparison to the 5-day schedule [19]. The results of this study confirm similar response rates, mortality and OS between both decitabine schedules, supporting the use of the standard dose. In contrast, there are no previously reported studies comparing different dose schedules for azacitidine. Again, no statistically significant differences were found in the ORR between the 5 days vs. the standard 7-day azacitidine regimen, which might support the off-label use of this more convenient regimen over the standard 7 days. However, based on the significantly higher 1-year mortality and lower OS observed in this study with the 5-day schedule of azacitidine, it is suggested that azacitidine administered on a schedule other than the indicated 7-day regimen may lead to inferior outcomes.

The OS of azacitidine-treated patients in this study (median, 10.04 months) was similar to that reported in the intention-to-treat population from an AZA-AML-001 trial (median, 10.4 months) [17], while patients on decitabine achieved a median OS of 8.79 months, slightly higher than that observed in the DACO-016 trial (7.7 months) [16]. A recent population-based survey showed similar survival (median OS, 7.1 vs. 8.2 months) for older AML patients treated with azacitidine or decitabine [42]. However, decitabine-treated patients were younger, had fewer comorbid conditions and were more likely to receive the standard dosing schedule than azacitidine-treated patients [42]. Indeed, after adjustment for all these factors in a multivariable analysis, the differences in survival remained statistically significant [42]. A network-meta-analysis including three randomised clinical trials showed that azacitidine improves the OS using SUCRA analysis compared to decitabine, but the authors concluded that the superiority of either agent could not be confirmed, and head-to-head clinical trials are still needed [43]. When the analysis is performed including only studies that used azacitidine and decitabine at standard doses, the median OS was again similar (10.83 months vs. 8.46 months). The results of this meta-analysis support the use of HMAs in the real-world setting and show that single-centre and retrospective cohorts exhibit a median OS that encompass the estimates in the phase 3 trials.

Currently, the combination of HMAs and venetoclax has become a standard of care for AML patients unfit for intensive chemotherapy. DiNardo et al. showed a 73% CR/CRi
rate for the combination of venetoclax with HMAs, with a median OS of 17.5 months [49]. Comparing HMAs, they found that response rates and the OS were similar between the venetoclax + azacitidine and venetoclax + decitabine cohorts [49].

A recent study of newly diagnosed AML patients by Pollyea et al. showed a CR/CRi rate of 71% in patients treated with venetoclax and azacitidine and of 74% in patients treated with venetoclax and decitabine [50], showing a higher CR/CRi duration for venetoclax + azacitidine (21.9 months) compared to venetoclax + decitabine (15.0 months) [50]. However, the OS did not differ between combination regimens (16.4 months for venetoclax + azacitidine and 16.2 months for venetoclax + decitabine) [50]. All these findings are in concordance with our results regarding the similarity of treatment outcomes using either azacitidine or decitabine in combination with venetoclax.

5. Conclusions

Despite remarkable heterogeneity between the different studies, we found no significant differences regarding the 1-year mortality and OS for azacitidine and decitabine (roughly 9 months) in AML patients. Furthermore, this study shows that there are no significant differences in the efficacy of 5-day versus 10-day schedules of decitabine. However, patients treated with a shortened 5-day azacitidine scheme showed worsening outcomes compared to the standard 7-day regimen. Hopefully, the results of this meta-analysis, exploring single HMA regimens, might be helpful for the design of HMA-based combination schedules to be tested in future trials.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13225677/s1, Figure S1: Overall response rate (ORR) analysis of azacitidine approved regimen (75mg/m² for 7 days) versus decitabine approved regimen (20mg/m² for 5 days), Figure S2: 1-year mortality analysis of azacitidine approved regimen (75mg/m² for 7 days) versus decitabine approved regimen (20mg/m² for 5 days), Figure S3: Overall survival (OS) analysis of azacitidine approved regimen (75mg/m² for 7 days) versus decitabine approved regimen (20mg/m² for 5 days), Table S1: Complete search strategy in the different reviewed databases.

Author Contributions: Conceptualization, M.S.-R. and J.L.; methodology, M.S.-R.; software, J.L.; validation, P.M.; formal analysis, M.S.-R.; investigation, M.S.-R., J.L., B.C., D.M.-C., V.C., R.A., I.C., M.A.S. and P.M.; resources, M.A.S.; data curation, M.S.-R.; writing—original draft preparation, M.S.-R.; writing—review and editing, J.L.; visualization, P.M.; supervision, M.A.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable. Since this study was a systematic review and meta-analysis, no approval from concerned review boards/committees (human/animal) was required.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Stone, A.; Zukerman, T.; Flaishton, L.; Ben Yakar, R.; Rowe, J.M. Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis. Leuk. Res. 2019, 82, 36–42. [CrossRef] [PubMed]
2. Juliesson, G.; Antunovic, P.; Derolf, A.; Lehmann, S.; Möllgård, L.; Stockelberg, D.; Tidefelt, U.; Wahlin, A.; Hoglund, M. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113, 4179–4187. [CrossRef] [PubMed]
3. Juliesson, G.; Lazarevic, V.; Hörstedt, A.-S.; Hagberg, O.; Hoglund, M. Acute myeloid leukemia in the real world: Why population-based registries are needed. Blood 2012, 119, 3890–3899. [CrossRef] [PubMed]
4. Visser, O.; Trama, A.; Maynadié, M.; Stiller, C.; Marcos-Gragera, R.; De Angelis, R.; Mallone, S.; Tereanu, C.; Allemani, C.; Ricardi, U.; et al. Incidence, survival and prevalence of myeloid malignancies in Europe. Eur. J. Cancer 2012, 48, 3257–3266. [CrossRef] [PubMed]
5. Shah, A.; Andersson, T.M.-L.; Rachet, B.; Björkholm, M.; Lambert, P.C. Survival and cure of acute myeloid leukaemia in England, 1971–2006: A population-based study. *Br. J. Haematol.* 2013, 162, 509–516. [CrossRef]

6. Martinez-Cuadrón, D.; Serrano, J.; Gil, C.; Tormo, M.; Martínez-Sánchez, P.; Pérez-Simón, J.A.; García-Boyer, R.; Rodríguez-Medina, C.; López-Pavia, M.; Benavente, C.; et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: Changing everything to change nothing? *Leukemia* 2021, 35, 1571–1585. [CrossRef]

7. Meyers, J.; Yu, Y.; Kaye, J.A.; Davis, K.L. Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs. *Appl. Health Econ. Health Policy* 2013, 11, 275–286. [CrossRef]

8. Erba, H.P. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. *Leuk. Res.* 2015, 39, 183–191. [CrossRef]

9. Buchner, T.; Berdel, W.E.; Haferlach, C.; Haferlach, T.; Schnittger, S.; Müller-Tidow, C.; Braess, J.; Spiekermann, K.; Kienast, J.; Staib, P.; et al. Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group. *J. Clin. Oncol.* 2009, 27, 61–69. [CrossRef]

10. Jabbour, E.; Kantarjian, H.; O’Brien, S.; Cortes, J.; Giles, F.; Faderl, S.; Garcia-Manero, G.; Wierda, W.; Pierce, S.; Shan, J.; et al. Results of Intensive Chemotherapy in 998 Patients Aged 65 Years or Older with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome—Predictive Prognostic Models for Outcome. *Blood* 2005, 106, 1846. [CrossRef]

11. Grimwade, D.; Walker, H.; Harrison, G.; Oliver, F.; Chatters, S.; Harrison, C.; Wheatley, K.; Burnett, A.K.; Goldstone, A.H. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. *Blood* 2001, 98, 1312–1320. [CrossRef]

12. Farag, S.S.; Archer, K.J.; Mr

13. Yoon, S.; Vincelette, N.D.; Abraham, I.; Robertson, K.; Fernandez-Zapico, M.E.; Patnaik, M.M. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: A systematic review of hypomethylating agents trials. *Clin. Epigenetics* 2016, 8, 68. [CrossRef] [PubMed]

14. Lyko, F.; Brown, R. DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies. *J. Natl. Cancer Inst.* 2005, 97, 1498–1506. [CrossRef] [PubMed]

15. Faderl, S.; Kantarjian, H.M. Clinical Manifestations and Treatment of Acute Myeloid Leukemia. *Hematology* 2018, 924–943. [CrossRef] [PubMed]

16. Dombret, H.; Seymour, J.F.; Butrym, A.; Wierzbowska, A.; Selleslag, D.; Jang, J.H.; Kumar, R.; Cavenagh, J.; Schuh, A.C.; Candoni, A.; et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed acute myeloid leukemia. *J. Clin. Oncol.* 2012, 30, 2670–2677. [CrossRef] [PubMed]

17. Dombret, H.; Seymour, J.F.; Butrym, A.; Wierzbowska, A.; Selleslag, D.; Jang, J.H.; Kumar, R.; Cavenagh, J.; Schuh, A.C.; Candoni, A.; et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: A randomised phase 2 trial. *Lancet Haematol.* 2018, 5, e29–e37. [CrossRef]

18. Al-Ali, H.K.; Jaekel, N.; Junghanss, C.; Maschmeyer, G.; Krahlf, R.; Cross, M.; Hoppe, G.; Niederrwieser, D. Azacitidine in patients with acute myeloid leukaemia medically unfit for or resistant to chemotherapy: A multicenter phase I/II study. *Leuk. Lymphoma* 2011, 53, 110–117. [CrossRef]

19. Passweg, J.R.; Pabst, T.; Blum, S.; Bargetzi, M.; Li, Q.; Heim, D.; Stussi, G.; Gregor, M.; Leoncini, L.; Meyer-Monard, S.; et al. Azacitidine for acute myeloid leukemia in elderly or frail patients: A phase II trial (SAKK 30/07). *Leuk. Lymphoma* 2015, 5677. 8, 56. [CrossRef] [PubMed]

20. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Altman, D.; Antes, G.; Atkins, D.; Barbour, V.; Barrowman, N.; Berlin, J.A.; et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *J. Clin. Epidemiol.* 2009, 62, 1006–1012. [CrossRef] [PubMed]

21. Döhner, H.; Estey, E.; Grimwade, D.; Amadori, S.; Appelbaum, F.R.; Büchner, T.; Dombret, H.; Ebert, B.L.; Fenaux, P.; Larson, R.A.; et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood* 2017, 129, 424–447. [CrossRef] [PubMed]

22. Higgins, J.P.T.; Green, S. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration. 2011. Available online: https://handbook-5.1.cochrane.org/ (accessed on 20 December 2019).

23. Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med. Res. Methodol.* 2005, 5, 13. [CrossRef] [PubMed]
26. Dinardo, C.D.; Jonas, B.A.; Pullarkat, V.; Thirman, M.J.; Garcia, J.S.; Wei, A.H.; Konopleva, M.; Döhner, H.; Letai, A.; Fenaux, P.; et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. *N. Engl. J. Med.* 2020, 383, 617–629. [CrossRef]

27. Falantes, J.; Pleyer, L.; Thépot, S.; Almeida, A.M.; Maurillo, L.; Martínez-Robles, V.; Stauder, R.; Itzykson, R.; Pinto, R.; Venditti, A.; et al. Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: Results from the expanded international E-ALMA series (E-ALMA+). *Leuk. Lymphoma* 2017, 59, 1113–1120. [CrossRef]

28. Fenaux, P.; Mufti, G.J.; Hellström-Lindberg, E.; Santini, V.; Gattermann, N.; Germing, U.; Sanz, G.; List, A.F.; Gore, S.; Seymour, J.F.; et al. Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia. *J. Clin. Oncol.* 2010, 28, 562–569. [CrossRef]

29. Medeiros, B.C.; McCaul, G.; Kambhampati, S.; Pollyea, D.A.; Kumar, R.; Silverman, L.R.; Kew, A.; Saini, L.; Beach, C.L.; Vij, R.; et al. Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. *Haematologica* 2017, 103, 101–106. [CrossRef]

30. Sadashiv, S.K.; Hilton, C.; Khan, C.; Rossetti, J.M.; Benjamin, H.L.; Fazal, S.; Sahovic, E.; Shadduck, R.K.; Lister, J. Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia. *Cancer Med.* 2014, 3, 1570–1578. [CrossRef]

31. Van der Helm, L.; Alhan, C.; Wijermans, P.W.; van Marwijk Kooy, M.; Schaafsma, R.; Biemond, B.J.; Beeker, A.; Hoogendoorn, M.; van Rees, B.; de Weerdt, O.; et al. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p: Azacitidine and Response Predictors in MDS, CML and AML. *Br. J. Haematol.* 2011, 155, 599–606.

32. Vives, S.; Martínez-Cuadrón, D.; Burgues, J.B.; Algarra, M.; Torno, M.; Martínez-Sánchez, M.P.; Serrano, J.; Herrera, P.; Ramos, F.; Salamero, O.; et al. Phase 3 trial of azacitidine versus a semi-intensive fluorarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. *Cancer 2021*, 127, 2033–2014. [CrossRef] [PubMed]

33. Bhatnagar, B.; Duong, V.H.; Gourdin, T.S.; Tidwell, M.L.; Chen, C.; Ning, Y.; Emadi, A.; Sausville, E.A.; Baer, M.R. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. *Leuk. Lymphoma* 2014, 55, 1533–1537. [CrossRef]

34. Bocchia, M.; Candoni, A.; Borlenghi, E.; Defina, M.; Fili, C.; Cattaneo, C.; Sammartano, V.; Fanin, R.; Sciumè, M.; Sicuranza, A.; et al. Real-world experience with decitabine as first-line treatment in 306 elderly acute myeloid leukemia patients unfit for intensive chemotherapy. *Hematol. Oncol. 2019*, 37, 447–455. [CrossRef] [PubMed]

35. Bouligny, I.M.; Mehta, V.; Isom, S.; Ellis, L.R.; Bhave, R.R.; Howard, D.S.; Lyerly, S.; Manuel, M.; Dralle, S.; Powell, B.L.; et al. Efficacy of 10-day decitabine in acute myeloid leukemia. *Leuk. Res. 2021*, 103, 106524. [CrossRef] [PubMed]

36. Cashen, A.F.; Schiller, G.J.; O’Donnell, M.R.; DiPersio, J.F. Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia. *J. Clin. Oncol.* 2010, 28, 556–561. [CrossRef] [PubMed]

37. Fili, C.; Candoni, A.; Zannier, M.E.; Olivieri, J.; Imbergamo, S.; Caizzi, M.; Nadali, G.; Di Bona, E.; Ermacora, A.; Gottardi, M.; et al. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience. *Leuk. Res. 2019*, 76, 33–38. [CrossRef] [PubMed]

38. Issa, J.-P.J.; Garcia-Manero, G.; Giles, F.J.; Mannari, R.; Thomas, D.; Faderl, S.; Bayar, E.; Lyons, J.; Rosenfeld, C.S.; Cortes, J.; et al. Phase 1 study of low-dose exposure schedules of a hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. *Blood 2004*, 103, 1635–1640. [CrossRef]

39. Jacob, L.A.; Aparna, S.; Lakshmaiah, K.C.; Lokanatha, D.; Babu, G.; Babu, S.; Appachu, S. Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness. *Adv. Hematol.* 2015, 2015, 167029. [CrossRef]

40. Lübbert, M.; Rüter, B.H.; Claus, R.; Schmoor, C.; Schmid, M.; Germing, U.; Kuendgen, A.; Rethwisch, V.; Ganser, A.; Platzbecker, U.; et al. Multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. *Haematologica* 2011, 97, 393–401. [CrossRef]

41. Roboz, G.J.; Mandrekar, S.J.; Desai, P.; Laumann, K.; Walker, A.R.; Wang, E.S.; Kolitz, J.E.; Powell, B.L.; Attar, E.C.; Stock, W.; et al. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). *Blood Adv.* 2018, 2, 3608–3617. [CrossRef]

42. Zeidan, A.M.; Wang, R.; Wang, X.; Shallis, R.M.; Podolsetev, N.A.; Bewersdorf, J.P.; Huntington, S.F.; Neparidze, N.; Giri, S.; Gore, S.D.; et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: A large population-based study in the United States. *Blood Adv.* 2020, 4, 2192–2201. [CrossRef] [PubMed]

43. Wen, B.; You, W.; Yang, S.; Du, X. Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: A systematic review and network meta-analysis. *Exp. Hematol. Oncol.* 2020, 9, 3. [CrossRef] [PubMed]

44. Grossmann, V.; Schnittger, S.; Kohlmann, A.; Eder, C.; Roller, A.; Dicker, F.; Schmid, C.; Wendtner, C.-M.; Staib, P.; Serve, H.; et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. *Blood 2012*, 120, 2963–2972. [CrossRef]

45. Rücker, F.G.; Schlenk, R.F.; Bullinger, L.; Kayser, S.; Teleanu, V.; Kett, H.; Habdank, M.; Kugler, C.M.; Holzmann, K.; Gaidzik, V.I.; et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomy karyotype, and dismal outcome. *Blood 2012*, 119, 2114–2121. [CrossRef]
46. Bories, P.; Prade, N.; Lagarde, S.; Cabarrou, B.; Largeaud, L.; Plenecassagnes, J.; Luquet, I.; De Mas, V.; Filleron, T.; Cassou, M.; et al. Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. *PLoS ONE* **2020**, *15*, e0238795. [CrossRef]

47. Welch, J.S.; Petti, A.A.; Miller, C.; Fronick, C.C.; O’Laughlin, M.; Fulton, R.S.; Wilson, R.K.; Baty, J.D.; Duncavage, E.J.; Tandon, B.; et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. *N. Engl. J. Med.* **2016**, *375*, 2023–2036. [CrossRef]

48. Aldoss, I.; Zhang, J.; Pillai, R.; Shouse, G.; Sanchez, J.F.; Mei, M.; Nakamura, R.; Stein, A.S.; Forman, S.J.; Marcucci, G.; et al. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. *Br. J. Haematol.* **2019**, *187*, e45–e48. [CrossRef] [PubMed]

49. Dinardo, C.D.; Pratz, K.; Pullarkat, V.; Jonas, B.; Arellano, M.; Becker, P.S.; Frankfurt, O.; Konopleva, M.; Wei, A.H.; Kantarjian, H.M.; et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. *Blood* **2019**, *133*, 7–17. [CrossRef]

50. Pollyea, D.A.; Pratz, K.; Letai, A.; Jonas, B.A.; Wei, A.H.; Pullarkat, V.; Konopleva, M.; Thirman, M.J.; Arellano, M.; Becker, P.S.; et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase Ib study. *Am. J. Hematol.* **2020**, *96*, 208–217. [CrossRef]